Outsourcing-Pharma.com presents its weekly round-up of the latest career climbers including news from CTI, AndersonBrecon and CIS.
Kathryn Wekselman has become director of regulatory and scientific affairs for CTI Clinical Trial and Consulting Services.
Previously, she served in the same role for INC Research.
Also new to the firm is former Cylex business development manager Tammy Dandrea. She takes on the role of assistant director of medical and scientific affairs.
Lynn Fallon, president of CTI Consulting Services, said: “Kathy brings a wealth of US and global regulatory experience expanding our current regulatory services.
“Tammy’s clinical, transplant and scientific writing experience is a perfect fit for the consulting and scientific affairs department.”
AndersonBrecon has reshuffled its management team with new roles for Peter Belden and Sue Miles.
Previously the European MD, Belden will become senior VP of global commercial services
Sue Miles will move from her current role as clinical trials and customer services director to become UK site director. She will now take charge of all UK facilities.
The Welsh firm said the appointments will help integrate the US and European businesses.
Belden said: “It is essential that the teams are able to embrace and share each other’s’ skills and expertise in a broad range of markets. We are confident that this will provide us with the combined knowledge and capabilities which will allow us to provide our customers with an all-encompassing skill-set following the pivotal re-brand.”
Publicis Healthcare Communications Group (PHCG) has named Shannon Boyle its new senior VP of human resources.
She joins the healthcare communications group firm from AstraZeneca where she was head of global talent development.
Landow to Accelerate Patient Intelligence Firm's Growth with Over a Decade of Healthcare and Advertising Agency Leadership Experience
Treato has appointed Yaron Landow as VP of US sales and business development.
He joins the Israel-based company – which specialises social network services to facilitate patient discussions – from Flashpoint Medica where he was head of business development and strategic services.
Landow said. "This unique technology brings clear business value to agencies and pharma marketers throughout the brand management lifecycle, enabling new insights from patients, advanced analytics and real-time engagement. I look forward to working with our customers and partners in bringing to market the next level in patient intelligence."
David Novak has been drafted in as president of Chemical Information Services (CIS), after serving as VP of marketing and strategy since 2011.
The move comes as part of a management shake-up, in which CEO John Harris has returned to his previous role as an operating partner at glendonTodd Capital - which invests in CIS.
Todd Furniss, chairman of the board at CIS and CEO of glendonTodd said: “We are grateful for John's contribution and service to CIS.
“David's marketing acumen, sales focus and attention to operational execution substantively expands our firm's leadership and functional competence.”